Can the GAHS be used in patients already on corticosteroids?

The GAHS was validated in treatment-naive patients. While calculable during treatment, corticosteroids may influence WBC values. For assessing response in patients already on steroids, the Lille score at day 7 is the recommended tool instead.

Glasgow Alcoholic Hepatitis Score (GAHS) Calculator- Free Alcoholic Hepatitis Prognosis Tool

Glasgow Alcoholic Hepatitis Score (GAHS) Calculator – Free Alcoholic Hepatitis Prognosis Tool | Super-Calculator.com

JavaScript Required

This Glasgow Alcoholic Hepatitis Score (GAHS) calculator requires JavaScript to compute the GAHS from age, white blood cell count, blood urea, prothrombin time ratio, and serum bilirubin, and to display 28-day and 84-day survival predictions with corticosteroid therapy guidance. Please enable JavaScript in your browser to use this free alcoholic hepatitis prognosis tool.

Glasgow Alcoholic Hepatitis Score (GAHS) Calculator

Calculate the Glasgow Alcoholic Hepatitis Score from five clinical and laboratory parameters to predict 28-day and 84-day mortality in alcoholic hepatitis. This validated prognostic tool helps guide corticosteroid therapy decisions by stratifying patients into lower-risk and high-risk categories based on the critical GAHS threshold of 9, as endorsed by the 2018 EASL clinical practice guidelines.

Important Medical Disclaimer

This calculator is provided for informational and educational purposes only. It is not intended to replace professional medical advice, diagnosis, or treatment. Always consult with a qualified healthcare professional before making any medical decisions. The results from this calculator should be used as a reference guide only and not as the sole basis for clinical decisions.

out of 12 (GAHS Score Range: 5-12)

5 – 8

9 – 10

11 – 12

5 (Min) — 9 Threshold — 12 (Max)

11-12

Very High Risk

Extremely poor prognosis. Urgent corticosteroid consideration and ICU monitoring.

9-10

High Risk – Consider Corticosteroids

28-day survival ~46% untreated. Corticosteroids can improve to ~78%.

7-8

Moderate – Monitor Closely

Below threshold but approaching risk zone. Reassess on days 6-9.

5-6

Lower Risk – Supportive Care

Favorable prognosis. 28-day survival ~87%. Corticosteroids not indicated.

28-Day Survival (Day 1)

87%

84-Day Survival (Day 1)

79%

Recommended: Supportive Care A GAHS of 5 (below 9) indicates relatively favorable short-term prognosis with approximately 87% 28-day survival. Supportive care with close monitoring is recommended. Reassess the GAHS on days 6-9 for updated prognostic information. Corticosteroid therapy is unlikely to provide additional benefit at this score level. Counsel on alcohol abstinence and ensure nutritional support.

Parameter	Score 1	Score 2	Score 3
Age (years)	< 50	>= 50	–
WBC (10^9/L)	< 15	>= 15	–
Urea (mmol/L)	< 5	>= 5	–
Urea (mg/dL)	< 14	>= 14	–
PT Ratio / INR	< 1.5	1.5 – 2.0	> 2.0
Bilirubin (umol/L)	< 125	125 – 250	> 250
Bilirubin (mg/dL)	< 7.3	7.3 – 14.6	> 14.6

Total GAHS = sum of all 5 component scores. Range: 5 (minimum) to 12 (maximum). A GAHS of 9 or above identifies patients with severe alcoholic hepatitis and poor short-term prognosis who may benefit from corticosteroid therapy. Reference: Forrest EH et al. Gut 2005;54:1174-1179.

Assessment Time	GAHS < 9	GAHS >= 9 (Untreated)	GAHS >= 9 (Steroids)
Day 1 – 28-Day Survival	87%	46%	78%
Day 1 – 84-Day Survival	79%	40%	—
Day 6-9 – 28-Day Survival	93%	47%	—
Day 6-9 – 84-Day Survival	86%	37%	—

Survival data from Forrest EH et al. (Gut 2005 and Gut 2007). Corticosteroid-treated survival refers to patients with mDF >= 32 and GAHS >= 9 who received prednisolone 40 mg/day. The Lille score at day 7 should be used to assess corticosteroid treatment response.

Conversion	Formula	Example	Notes
Bilirubin umol/L to mg/dL	mg/dL = umol/L / 17.1	125 umol/L = 7.3 mg/dL	SI units common outside USA
Bilirubin mg/dL to umol/L	umol/L = mg/dL x 17.1	7.3 mg/dL = 125 umol/L	Conventional units common in USA
Urea mmol/L to mg/dL	mg/dL = mmol/L x 2.8	5 mmol/L = 14 mg/dL	Blood urea, not BUN
BUN to Urea (mg/dL)	Urea = BUN x 2.14	BUN 6.5 = Urea ~14 mg/dL	If your lab reports BUN
BUN to Urea (mmol/L)	Urea = BUN x 0.357	BUN 14 = Urea ~5 mmol/L	Convert BUN to SI urea

Different laboratories worldwide report bilirubin and urea in different unit systems. Always verify which units your laboratory uses before entering values into the GAHS calculator. SI units (umol/L, mmol/L) are standard in many countries, while conventional units (mg/dL) are standard in the United States and some other regions.

Important Medical Disclaimer

About This Glasgow Alcoholic Hepatitis Score (GAHS) Calculator

This free Glasgow Alcoholic Hepatitis Score calculator is designed for healthcare professionals, hepatologists, gastroenterologists, and medical students who need to quickly assess prognosis in patients with alcoholic hepatitis. The GAHS calculator computes a composite score from five clinical and laboratory parameters — patient age, white blood cell count, blood urea, prothrombin time ratio (or INR), and serum bilirubin — to predict 28-day and 84-day mortality risk.

The calculator implements the validated GAHS scoring criteria published by Forrest and colleagues in Gut (2005), using the exact parameter thresholds from the original derivation and validation studies. It supports both SI units (umol/L for bilirubin, mmol/L for urea) and conventional units (mg/dL) to serve clinical users worldwide. The critical threshold of 9 for risk stratification is based on receiver operating curve analysis that simultaneously maximized sensitivity and specificity, as endorsed by the 2018 EASL clinical practice guidelines.

The calculator features a horizontal gradient progress bar showing where the patient’s GAHS falls on the severity scale, stacked accordion input cards with clinical context for each parameter, a risk ladder visualization with four severity tiers, and survival pill displays showing estimated 28-day and 84-day outcomes. Reference tabs provide the complete scoring table, validation study survival data, and unit conversion formulas for global clinical use.

Glasgow Alcoholic Hepatitis Score (GAHS) Calculator: Complete Guide to Predicting Outcomes in Alcoholic Hepatitis

Alcoholic hepatitis represents one of the most severe manifestations of alcohol-associated liver disease (ALD), carrying a short-term mortality rate that can exceed 50% in its most severe forms. Clinicians managing these critically ill patients require reliable prognostic tools to guide treatment decisions, particularly regarding the initiation of corticosteroid therapy. The Glasgow Alcoholic Hepatitis Score (GAHS) was developed specifically to address this need, offering superior predictive accuracy compared to older scoring systems such as the modified Maddrey Discriminant Function (mDF).

First described by Forrest and colleagues in 2005, the GAHS emerged from a study of 241 patients at hospitals throughout the United Kingdom. The score incorporates five readily available clinical and laboratory parameters: patient age, white blood cell count, blood urea nitrogen, prothrombin time ratio, and serum bilirubin. By combining these variables into a composite score ranging from 5 to 12, the GAHS provides clinicians with a practical bedside tool that can be calculated on admission day or reassessed on days 6 through 9 of hospitalization.

This calculator allows healthcare professionals to quickly compute the GAHS, interpret the results in the context of 28-day and 84-day survival data, and make informed decisions about corticosteroid therapy. Understanding how to use this scoring system effectively can significantly impact patient management and outcomes in this challenging clinical scenario.

What Is the Glasgow Alcoholic Hepatitis Score?

The Glasgow Alcoholic Hepatitis Score is a clinical prognostic scoring system designed to predict mortality in patients with alcoholic hepatitis. Unlike earlier scoring systems that relied primarily on liver function tests, the GAHS incorporates an inflammatory parameter (white blood cell count) alongside markers of hepatic synthetic function, renal function, and patient age. This multidimensional approach reflects the complex pathophysiology of alcoholic hepatitis, which involves both hepatocellular damage and systemic inflammatory response.

The score was derived through multiple stepwise logistic regression analysis of clinical and laboratory variables collected from a large patient cohort. Five variables were identified as independently associated with patient outcome: age, serum bilirubin, blood urea, prothrombin time (expressed as a ratio of control value), and peripheral blood white cell count. Each variable is assigned a score of 1, 2, or 3 based on specific thresholds, and the total score is obtained by summing the individual component scores.

A GAHS of 9 or higher identifies patients at highest risk of death. In the original validation study, the score demonstrated an overall accuracy of 81% when predicting 28-day outcome, substantially outperforming the modified discriminant function, which had an overall accuracy of only 49%. This improved accuracy makes the GAHS a more reliable guide for clinical decision-making.

Glasgow Alcoholic Hepatitis Score Formula

GAHS = Age Score + WBC Score + Urea Score + PT Ratio Score + Bilirubin Score

Each parameter is scored 1, 2, or 3 based on threshold values. The total score ranges from 5 (minimum, all parameters score 1) to 12 (maximum). Age and WBC are scored as either 1 or 2 (no score of 3), while PT ratio and bilirubin can score up to 3. A score of 9 or greater indicates severe disease with poor prognosis.

GAHS Scoring Parameters and Thresholds

Understanding each component of the GAHS and its clinical significance is essential for accurate score calculation and interpretation. The five parameters were selected because each independently predicts mortality in alcoholic hepatitis, and together they capture the major pathophysiological domains affected by the disease.

Age

Patients younger than 50 years receive a score of 1, while those aged 50 or older receive a score of 2. Age is a well-established prognostic factor in liver disease generally, reflecting both the cumulative hepatic insult from prolonged alcohol exposure and the diminished regenerative capacity of the aging liver. Older patients also tend to have more comorbidities that complicate their clinical course.

White Blood Cell Count (WBC)

A WBC below 15 x 10^9/L scores 1, while a count of 15 or greater scores 2. This parameter captures the systemic inflammatory response that characterizes severe alcoholic hepatitis. Elevated white cell counts reflect the intense neutrophilic infiltration of the liver and the broader inflammatory cascade triggered by hepatocyte necrosis and endotoxin exposure from increased gut permeability.

Blood Urea

Urea below 5 mmol/L (or below 14 mg/dL in conventional units) scores 1, while urea of 5 mmol/L or above (14 mg/dL or above) scores 2. Elevated urea reflects renal impairment, which is a significant adverse prognostic factor in alcoholic hepatitis. Renal dysfunction in this setting may result from hepatorenal syndrome, volume depletion, or direct nephrotoxic effects, and its presence substantially worsens the clinical outlook.

Prothrombin Time Ratio

A PT ratio below 1.5 scores 1, a ratio between 1.5 and 2.0 scores 2, and a ratio above 2.0 scores 3. The prothrombin time ratio is a sensitive marker of hepatic synthetic function, reflecting the liver’s ability to produce coagulation factors. Significant prolongation indicates severe hepatocellular dysfunction and is one of the strongest individual predictors of mortality in alcoholic hepatitis.

Serum Bilirubin

Bilirubin below 125 micromol/L (below 7.3 mg/dL) scores 1, between 125 and 250 micromol/L (7.3 to 14.6 mg/dL) scores 2, and above 250 micromol/L (above 14.6 mg/dL) scores 3. Serum bilirubin is a direct marker of hepatic excretory function and cholestasis. Profoundly elevated bilirubin levels indicate extensive hepatocyte damage and intrahepatic cholestasis, both of which carry poor prognostic implications.

GAHS Parameter Scoring Table (SI Units)

Age: <50 = 1 | >=50 = 2
WBC (10^9/L): <15 = 1 | >=15 = 2
Urea (mmol/L): <5 = 1 | >=5 = 2
PT Ratio: <1.5 = 1 | 1.5-2.0 = 2 | >2.0 = 3
Bilirubin (umol/L): <125 = 1 | 125-250 = 2 | >250 = 3

Note: For urea in conventional units (mg/dL), the threshold is 14 mg/dL. For bilirubin in conventional units, thresholds are 7.3 mg/dL and 14.6 mg/dL. To convert bilirubin from umol/L to mg/dL, divide by 17.1. To convert urea from mmol/L to mg/dL, multiply by 2.8.

Interpreting the GAHS: Survival Data and Clinical Significance

The clinical utility of the GAHS lies in its ability to stratify patients into distinct prognostic groups. The critical threshold is a score of 9: patients scoring below 9 have a substantially better prognosis than those scoring 9 or above, and this distinction has direct therapeutic implications.

When calculated on the day of admission (day 1), patients with a GAHS below 9 have approximately 87% survival at 28 days and 79% survival at 84 days. In contrast, patients with a GAHS of 9 or above have dramatically reduced survival rates of approximately 46% at 28 days and 40% at 84 days in the absence of treatment. This nearly twofold difference in mortality highlights the prognostic power of the scoring system.

The score can also be recalculated on days 6 through 9 of hospitalization, providing updated prognostic information that may reflect the patient’s response to initial management. When assessed at this later timepoint, patients with a GAHS below 9 show even better outcomes (93% 28-day survival, 86% 84-day survival), suggesting that sustained low scores confirm a favorable trajectory. Conversely, patients maintaining a GAHS of 9 or above at days 6 through 9 have persistently poor outcomes (47% 28-day survival, 37% 84-day survival).

Key Point: The Critical Threshold of 9

A GAHS of 9 or greater identifies patients with severe alcoholic hepatitis who have the highest risk of short-term mortality. These patients may benefit most from corticosteroid therapy. Patients with a GAHS below 9, even if they have an mDF of 32 or greater, appear to have acceptable short-term survival without corticosteroid treatment.

GAHS and Treatment Decisions: Corticosteroid Therapy

One of the most important clinical applications of the GAHS is guiding decisions about corticosteroid therapy in alcoholic hepatitis. The 2018 European Association for the Study of the Liver (EASL) clinical practice guidelines endorse the GAHS, alongside the mDF and the Lille score, as prognostic tools in the management of alcohol-related liver disease.

The key finding from validation studies is that corticosteroid therapy appears to benefit primarily those patients with a GAHS of 9 or above. In a study of 225 patients with severe alcoholic hepatitis (mDF greater than or equal to 32), Forrest and colleagues demonstrated that among patients with a GAHS of 9 or above, corticosteroid-treated individuals had a 28-day survival of 78% compared with only 52% in untreated patients. The 84-day survival showed an even more pronounced difference.

Importantly, among patients with a GAHS below 9 (even those with an mDF of 32 or greater), there was no significant difference in survival between corticosteroid-treated and untreated patients. This suggests that the GAHS may be more specific than the mDF in identifying patients who will actually benefit from corticosteroid therapy, potentially sparing those with lower scores from the adverse effects of corticosteroids.

Key Point: Treatment Guidance

Patients with a GAHS of 9 or above and an mDF of 32 or greater represent the group most likely to benefit from corticosteroid therapy. The standard regimen is prednisolone 40 mg daily for 28 days. The Lille score should be calculated at day 7 to assess treatment response and determine whether to continue or discontinue corticosteroids.

Comparison with Other Prognostic Scoring Systems

Several prognostic scoring systems exist for alcoholic hepatitis, each with strengths and limitations. Understanding how the GAHS compares with these alternatives helps clinicians choose the most appropriate tool for their clinical scenario.

Modified Maddrey Discriminant Function (mDF)

The mDF was the first widely used prognostic score for alcoholic hepatitis, calculated as 4.6 multiplied by the difference between patient and control prothrombin times, plus the serum bilirubin in mg/dL. While highly sensitive (rarely missing high-risk patients), the mDF has poor specificity, incorrectly predicting poor outcomes in up to 51% of cases. The GAHS demonstrated significantly greater overall accuracy at both 28 and 84 days compared to the mDF.

MELD Score

The Model for End-Stage Liver Disease (MELD) score, originally developed for liver transplant prioritization, has also been applied to alcoholic hepatitis prognosis. While the MELD incorporates bilirubin, INR, and creatinine, the GAHS has shown comparable or superior accuracy in predicting outcomes specifically in alcoholic hepatitis populations. The GAHS advantage lies in its inclusion of inflammatory markers and its simplicity of calculation.

ABIC Score

The Age-Bilirubin-INR-Creatinine (ABIC) score stratifies patients into low, intermediate, and high-risk categories. While useful for risk stratification, the ABIC does not include inflammatory parameters and has not been as extensively validated for guiding corticosteroid therapy decisions as the GAHS.

Lille Score

The Lille score is calculated at day 7 of corticosteroid treatment and is used to assess treatment response rather than initial prognosis. It complements the GAHS by helping determine whether to continue or discontinue corticosteroid therapy. A Lille score of 0.45 or above suggests non-response to corticosteroids.

Unit Conversion Formulas for Global Users

Bilirubin: mg/dL = umol/L / 17.1
Urea: mg/dL = mmol/L x 2.8
BUN (mg/dL) = Urea (mmol/L) x 2.8 / 2.14

Different laboratories worldwide report values in different units. Always check which unit system your laboratory uses before entering values. SI units (umol/L for bilirubin, mmol/L for urea) are common in many countries, while conventional units (mg/dL) are standard in others, including the United States.

Global Application and Population Considerations

The GAHS was originally derived from a predominantly United Kingdom-based patient population and validated across eight hospital centers in the UK. Since its publication, the score has been studied and applied in diverse clinical settings across Europe, North America, Asia, and other regions worldwide. While the score appears to perform well across different populations, clinicians should be aware of potential variations in performance related to patient demographics and disease patterns.

Some studies suggest that the performance of prognostic scores in alcoholic hepatitis may vary across different ethnic populations, reflecting differences in genetic susceptibility to alcohol-related liver injury, patterns of alcohol consumption, and prevalence of cofactors such as viral hepatitis and metabolic syndrome. Healthcare providers should consider these population-specific factors when interpreting GAHS results.

It is also important to note that the GAHS was validated in patients with a serum bilirubin level of 80 umol/L or greater and a history of excessive alcohol consumption (50 grams per day or more). Application of the score outside these parameters may yield less reliable results. The original study excluded patients with viral hepatitis, autoimmune liver disease, biliary obstruction, or hepatocellular carcinoma.

Clinical Workflow: How to Use the GAHS in Practice

Implementing the GAHS in clinical practice involves a systematic approach to patient assessment and decision-making. On admission, the clinician should obtain the five required parameters from routine blood tests and patient history. The score is then calculated and interpreted in the context of the patient’s overall clinical picture.

For patients with a GAHS below 9, supportive care with close monitoring is generally appropriate. These patients have a relatively favorable short-term prognosis and may not require corticosteroid therapy. However, the score should be reassessed on days 6 through 9 to detect any deterioration that might change the management plan.

For patients with a GAHS of 9 or above, consideration should be given to initiating corticosteroid therapy (prednisolone 40 mg daily) if no contraindications are present. Contraindications to corticosteroids in this setting include active infection, gastrointestinal bleeding, hepatorenal syndrome, and pancreatitis. If corticosteroids are initiated, the Lille score should be calculated at day 7 to assess treatment response.

Throughout this process, the GAHS should be used as one component of a comprehensive clinical assessment, not as the sole determinant of treatment decisions. Individual patient factors, comorbidities, contraindications, and the clinical trajectory all contribute to optimal management.

Key Point: Contraindications to Corticosteroids

Before initiating corticosteroid therapy based on a high GAHS, clinicians must screen for contraindications including active sepsis or uncontrolled infection, active gastrointestinal bleeding, hepatorenal syndrome, pancreatitis, and poorly controlled diabetes mellitus. These conditions may preclude corticosteroid use regardless of the GAHS value.

Limitations of the GAHS

While the GAHS represents an improvement over earlier scoring systems, it has several limitations that clinicians should acknowledge. The score was derived primarily from patients with bilirubin levels of 80 umol/L or greater, so its applicability to patients with lower bilirubin levels (milder disease) is uncertain.

The prothrombin time component presents challenges because PT measurement is not standardized across laboratories. Different reagents and methodologies can produce varying results for the same patient sample. While expressing PT as a ratio of control partially addresses this issue, some interlaboratory variability persists. In settings where INR is available instead of PT ratio, the GAHS can be adapted, although the original validation used PT ratio specifically.

The score does not incorporate all known prognostic factors in alcoholic hepatitis. Parameters such as creatinine (reflecting renal function more specifically than urea), hepatic encephalopathy, and emerging biomarkers like C-reactive protein and cytokeratin-18 are not included. As understanding of alcoholic hepatitis pathophysiology deepens, future scoring systems may incorporate additional variables for improved accuracy.

Finally, the GAHS does not predict response to specific treatments. While it can identify patients likely to benefit from corticosteroids, it cannot predict which individual patients will respond favorably. The Lille score remains the standard tool for assessing corticosteroid response at day 7 of treatment.

Pathophysiology of Alcoholic Hepatitis

Understanding the pathophysiology underlying each GAHS component provides insight into why these particular variables predict outcomes. Alcoholic hepatitis results from a complex interplay between direct alcohol-mediated hepatotoxicity, oxidative stress, gut-derived endotoxemia, and dysregulated immune responses.

Chronic alcohol consumption damages the intestinal barrier, leading to increased translocation of bacterial endotoxins (lipopolysaccharides) from the gut into the portal circulation. These endotoxins activate hepatic Kupffer cells, triggering the release of pro-inflammatory cytokines including tumor necrosis factor-alpha (TNF-alpha), interleukin-1, and interleukin-6. This inflammatory cascade results in hepatocyte necrosis and apoptosis, neutrophilic infiltration (reflected in elevated WBC), impaired protein synthesis (reflected in prolonged PT), impaired bilirubin metabolism (reflected in elevated bilirubin), and secondary organ dysfunction (reflected in elevated urea).

The inclusion of age in the score reflects both the cumulative hepatotoxic burden and the age-related decline in hepatic regenerative capacity. Older patients are less able to mount an effective repair response following acute hepatic injury, contributing to worse outcomes.

Prothrombin Time Ratio: Calculation and Considerations

The prothrombin time ratio is calculated by dividing the patient’s PT by the laboratory control PT. This normalization allows comparison across different laboratories that may use different thromboplastin reagents. A ratio of 1.0 indicates normal coagulation, while higher ratios indicate progressively impaired hepatic synthetic function.

In some clinical settings, the International Normalized Ratio (INR) is reported instead of or alongside the PT ratio. While the INR was designed to standardize PT measurement for monitoring warfarin therapy, it can serve as a reasonable substitute for the PT ratio in the GAHS calculation. The original validation study included a subgroup analysis using INR in place of PT ratio and found comparable performance.

As a practical guide, an INR of approximately 1.5 corresponds roughly to a PT ratio of 1.5, and an INR of approximately 2.0 corresponds to a PT ratio of approximately 2.0, although the exact correspondence depends on laboratory-specific factors. Clinicians should use the measure that is most readily available and reliable in their institution.

Prothrombin Time Ratio Calculation

PT Ratio = Patient PT (seconds) / Control PT (seconds)

The control PT is the normal PT value established by the laboratory, typically around 12 to 14 seconds. If your laboratory reports INR instead of PT ratio, the INR can be used as a reasonable substitute for the PT ratio in GAHS calculation.

When to Use the GAHS

The GAHS is most appropriately applied in the following clinical scenarios: patients presenting with clinical features of alcoholic hepatitis including jaundice, hepatomegaly, and recent history of heavy alcohol consumption; patients with a serum bilirubin of 80 umol/L (4.7 mg/dL) or greater in the context of alcohol-associated liver disease; on admission day (day 1) for initial prognostic assessment; and on days 6 through 9 for reassessment and updated prognostic information.

The score should not be applied to patients whose liver disease is primarily attributable to causes other than alcohol, such as viral hepatitis, drug-induced liver injury, autoimmune hepatitis, or biliary obstruction. It is also not validated for use in patients with hepatocellular carcinoma or in the post-transplant setting.

Clinical judgment should always accompany the numerical score. A patient with a GAHS below 9 who is clinically deteriorating may warrant more aggressive management, while a patient with a GAHS of 9 or above who has clear contraindications to corticosteroids requires alternative management strategies.

Evidence Base and Validation Studies

The GAHS was originally derived from a dataset of 241 patients from Glasgow and validated in a separate cohort of 195 patients from eight hospitals across the United Kingdom. The derivation study was published by Forrest and colleagues in Gut in 2005. None of the patients in the derivation or initial validation cohorts had received corticosteroids, pentoxifylline, or anti-TNF treatment, providing clean outcome data unconfounded by treatment effects.

Subsequent validation was performed in a treatment study of 225 patients with severe alcoholic hepatitis (mDF of 32 or greater) from five UK centers, published in the journal Gut in 2007. This study demonstrated that the GAHS could identify which patients with severe alcoholic hepatitis would benefit from corticosteroid therapy, adding treatment-guiding utility to its prognostic value.

The score has since been referenced in multiple international guidelines, including the 2018 EASL Clinical Practice Guidelines on Management of Alcohol-Related Liver Disease, which endorses the GAHS alongside the mDF and Lille score as part of the prognostic assessment toolkit for alcoholic hepatitis.

Alternative Regional Scoring Systems

While the GAHS has gained international recognition, several other scoring systems are available for assessing prognosis in alcoholic hepatitis. The choice of scoring system may depend on institutional preference, available laboratory parameters, and the specific clinical question being addressed.

The MELD score, widely used in North America for liver transplant prioritization, has been applied to alcoholic hepatitis with a suggested cutoff of 21 or greater indicating severe disease. The ABIC score, developed from European cohorts, stratifies patients into three risk categories. The AHHS (Alcoholic Hepatitis Histological Score) uses liver biopsy findings but is limited by the need for tissue sampling. Each scoring system offers a different perspective on disease severity, and using multiple scores in combination may provide the most comprehensive prognostic assessment.

Practical Tips for Accurate GAHS Calculation

To ensure accurate GAHS calculation, clinicians should be mindful of several practical considerations. First, confirm that blood samples are drawn on the correct day, whether for day 1 assessment (admission) or day 6 through 9 reassessment. Second, verify the units reported by the laboratory for bilirubin (umol/L versus mg/dL) and urea (mmol/L versus mg/dL) before entering values. Third, when using the PT ratio, ensure that the control PT value is current and specific to the laboratory’s reagent system. Fourth, be aware that the WBC count may be influenced by factors other than alcoholic hepatitis, such as concurrent infection or medications, which should be considered in the clinical context.

It is also advisable to calculate both the GAHS and the mDF, as the combination provides a more complete picture. Patients with both a GAHS of 9 or above and an mDF of 32 or above represent the highest-risk group with the clearest indication for corticosteroid therapy.

Frequently Asked Questions

What is the Glasgow Alcoholic Hepatitis Score (GAHS)?

The Glasgow Alcoholic Hepatitis Score is a clinical prognostic tool that predicts mortality in patients with alcoholic hepatitis. It was developed by Forrest and colleagues at hospitals in the United Kingdom and published in 2005. The score uses five readily available clinical and laboratory parameters (age, white blood cell count, blood urea, prothrombin time ratio, and serum bilirubin) to generate a composite score ranging from 5 to 12. A score of 9 or above indicates severe disease with poor short-term prognosis and identifies patients who may benefit from corticosteroid therapy.

How is the GAHS calculated?

The GAHS is calculated by scoring each of five parameters and summing the individual scores. Age is scored 1 (under 50) or 2 (50 or older). White blood cell count is scored 1 (under 15 x 10^9/L) or 2 (15 or greater). Blood urea is scored 1 (under 5 mmol/L or under 14 mg/dL) or 2 (5 or greater mmol/L or 14 or greater mg/dL). Prothrombin time ratio is scored 1 (under 1.5), 2 (1.5 to 2.0), or 3 (above 2.0). Serum bilirubin is scored 1 (under 125 umol/L), 2 (125 to 250 umol/L), or 3 (above 250 umol/L). The total ranges from 5 to 12.

What does a GAHS score of 9 or above mean?

A GAHS of 9 or above indicates that the patient has severe alcoholic hepatitis with a poor short-term prognosis. In the original validation study, patients with a day 1 GAHS of 9 or above had a 28-day survival of only 46% and an 84-day survival of 40% without treatment. These patients are considered candidates for corticosteroid therapy, which has been shown to improve survival in this high-risk group. A score of 9 or above warrants urgent clinical attention and consideration of treatment options.

What does a GAHS below 9 mean?

A GAHS below 9 indicates a relatively more favorable prognosis, with 28-day survival of approximately 87% and 84-day survival of approximately 79% when calculated on admission day. These patients generally do not appear to benefit from corticosteroid therapy, even if their mDF is 32 or greater. However, a score below 9 does not mean the patient is risk-free, and close monitoring with reassessment on days 6 through 9 is recommended to detect any clinical deterioration.

When should the GAHS be calculated?

The GAHS should be calculated on the day of admission (day 1) for initial prognostic assessment and can be recalculated on days 6 through 9 for updated prognostic information. The day 1 score helps guide initial treatment decisions, while the later reassessment reflects the patient’s clinical trajectory and response to supportive care. Both timepoints have been validated for predicting 28-day and 84-day outcomes.

How does the GAHS compare to Maddrey Discriminant Function?

The GAHS has been shown to be more accurate than the modified Maddrey Discriminant Function (mDF) in predicting outcomes in alcoholic hepatitis. While the mDF is highly sensitive, it has poor specificity, incorrectly predicting poor outcomes in approximately 51% of cases. The GAHS demonstrated an overall accuracy of 81% for 28-day outcomes compared to 49% for the mDF. The GAHS also better identifies which patients will actually benefit from corticosteroid therapy, as some patients with high mDF but low GAHS may not need corticosteroids.

Can INR be used instead of PT ratio in the GAHS?

Yes, the INR can be used as a reasonable substitute for the PT ratio when calculating the GAHS. The original validation study included a subgroup analysis using INR in place of PT ratio and found comparable performance. An INR of approximately 1.5 corresponds roughly to a PT ratio of 1.5, and an INR of approximately 2.0 corresponds to a PT ratio of approximately 2.0. If your laboratory reports INR rather than PT ratio, you may enter the INR value using the same thresholds.

What are the units for bilirubin in the GAHS?

The GAHS uses serum bilirubin thresholds in both SI units (micromol/L) and conventional units (mg/dL). In SI units, the thresholds are less than 125 umol/L (score 1), 125 to 250 umol/L (score 2), and above 250 umol/L (score 3). In conventional units, these correspond to less than 7.3 mg/dL, 7.3 to 14.6 mg/dL, and above 14.6 mg/dL respectively. To convert from umol/L to mg/dL, divide by 17.1.

What units are used for blood urea in the GAHS?

The GAHS uses blood urea with a threshold of 5 mmol/L in SI units or 14 mg/dL in conventional units. It is important to note that this refers to blood urea, not blood urea nitrogen (BUN). The conversion factor from urea in mmol/L to mg/dL is 2.8 (multiply mmol/L by 2.8 to get mg/dL as urea). If your laboratory reports BUN instead of urea, multiply BUN by 2.14 to obtain the urea value in mg/dL, or multiply BUN by 0.357 to convert to mmol/L.

Does the GAHS predict response to corticosteroid therapy?

The GAHS identifies patients who are most likely to benefit from corticosteroid therapy (those with a score of 9 or above) but does not predict individual treatment response. To assess actual treatment response, the Lille score should be calculated at day 7 of corticosteroid therapy. A Lille score below 0.45 suggests a favorable response, while a score of 0.45 or above indicates non-response and may prompt discontinuation of corticosteroids to avoid unnecessary side effects.

What is the range of possible GAHS values?

The GAHS ranges from a minimum of 5 to a maximum of 12. The minimum of 5 occurs when all five parameters receive the lowest score of 1 each. The maximum of 12 is possible because age and WBC can score up to 2, urea can score up to 2, while PT ratio and bilirubin can each score up to 3 (2 + 2 + 2 + 3 + 3 = 12). There is a marked increase in mortality when the score reaches 9 or above.

Is the GAHS applicable to all types of liver disease?

No, the GAHS is specifically designed for and validated in patients with alcoholic hepatitis. It should not be applied to patients whose liver disease is primarily caused by viral hepatitis, autoimmune liver disease, drug-induced liver injury, biliary obstruction, or other non-alcohol-related causes. The original studies excluded patients with these conditions. For prognostic assessment in other liver diseases, more appropriate scoring systems such as MELD, Child-Pugh, or disease-specific scores should be used.

What patient criteria must be met before applying the GAHS?

The GAHS was validated in patients who had a serum bilirubin of 80 umol/L (approximately 4.7 mg/dL) or greater, a history of excessive alcohol ingestion (50 grams per day or more) until at least three weeks before admission, and no evidence of viral hepatitis, autoimmune liver disease, biliary obstruction, or hepatocellular carcinoma. Applying the score to patients who do not meet these criteria may yield unreliable results.

How does age affect the GAHS?

Age is one of the five scoring parameters in the GAHS. Patients under 50 years of age receive a score of 1, while those aged 50 or older receive a score of 2. This reflects the well-established observation that older patients with alcoholic hepatitis tend to have worse outcomes, likely due to reduced hepatic regenerative capacity, longer cumulative alcohol exposure, and more frequent comorbidities. The age threshold of 50 was identified through statistical analysis as the most discriminating cutpoint.

What is the significance of white blood cell count in the GAHS?

The white blood cell count is a unique feature of the GAHS that distinguishes it from many other liver disease scoring systems. Elevated WBC (15 x 10^9/L or greater) reflects the systemic inflammatory response characteristic of severe alcoholic hepatitis. Neutrophilic infiltration of the liver is a hallmark pathological feature, and the degree of systemic inflammation correlates with disease severity and mortality risk. This inflammatory marker adds prognostic information beyond what hepatic function tests alone can provide.

Can the GAHS be used alongside other scoring systems?

Yes, using the GAHS alongside other scoring systems is recommended for a comprehensive prognostic assessment. The GAHS and mDF complement each other: the mDF provides high sensitivity for detecting severe disease, while the GAHS offers better specificity and overall accuracy. The Lille score should be calculated at day 7 of corticosteroid treatment to assess response. The MELD score may provide additional prognostic perspective. Using multiple scores in combination gives clinicians a more complete picture of disease severity and likely outcome.

What survival rates are associated with different GAHS values?

Day 1 GAHS below 9 is associated with approximately 87% 28-day survival and 79% 84-day survival. Day 1 GAHS of 9 or above is associated with approximately 46% 28-day survival and 40% 84-day survival without treatment. When recalculated on days 6 through 9, a score below 9 carries 93% 28-day and 86% 84-day survival, while a score of 9 or above carries 47% 28-day and 37% 84-day survival. Corticosteroid treatment can improve 28-day survival to 78% in the high-GAHS group.

How does the GAHS help with corticosteroid decision-making?

The GAHS helps identify which patients with severe alcoholic hepatitis will benefit from corticosteroid therapy. Studies show that patients with a GAHS of 9 or above have significantly improved survival with corticosteroids compared to untreated patients. Conversely, patients with a GAHS below 9 show no significant survival benefit from corticosteroids, even if their mDF is 32 or greater. This specificity helps clinicians avoid exposing lower-risk patients to the potential adverse effects of corticosteroid therapy while ensuring high-risk patients receive appropriate treatment.

What are the limitations of the GAHS?

Key limitations include: the score was derived from a predominantly UK-based population; PT measurement is not standardized across laboratories; the score does not include all known prognostic factors such as creatinine, hepatic encephalopathy, or inflammatory biomarkers; it was validated primarily in patients with bilirubin above 80 umol/L; and it does not predict individual treatment response. Additionally, the scoring thresholds are somewhat arbitrary, and patients near the threshold of 9 may require additional clinical judgment rather than rigid adherence to the score alone.

What is the role of blood urea in the GAHS?

Blood urea in the GAHS serves as an indicator of renal function. Elevated urea (5 mmol/L or above, or 14 mg/dL or above) reflects renal impairment, which is an important adverse prognostic factor in alcoholic hepatitis. Renal dysfunction in this setting may result from hepatorenal syndrome, hypovolemia, acute kidney injury from systemic inflammation, or direct nephrotoxic effects. The presence of renal impairment significantly worsens the clinical outlook and adds an important dimension to the prognostic assessment beyond hepatic function alone.

How quickly can the GAHS change?

The GAHS can change over the course of hospitalization as the underlying clinical parameters evolve. Laboratory values such as bilirubin, PT, WBC, and urea may fluctuate in response to disease progression, treatment, or complications. This is why the score is designed to be calculated both on admission (day 1) and again on days 6 through 9. A patient whose score improves below 9 by days 6 through 9 has a better prognosis than one whose score remains elevated, providing dynamic prognostic information.

Is the GAHS validated in populations outside the United Kingdom?

The GAHS was originally derived and validated in UK hospital populations. While it has been subsequently studied and referenced in international guidelines, including the EASL 2018 guidelines, comprehensive validation across diverse global populations is more limited. Some studies have assessed its performance in European, Asian, and North American populations with generally favorable results. However, clinicians should be aware that performance may vary in populations that differ significantly from the original derivation cohort in terms of ethnicity, disease patterns, or clinical management.

What is alcoholic hepatitis and who develops it?

Alcoholic hepatitis is an acute inflammatory liver condition caused by prolonged and excessive alcohol consumption, typically defined as 50 grams or more per day over an extended period. It is characterized by jaundice, hepatomegaly, fever, and laboratory findings including elevated bilirubin and prolonged coagulation times. Not all heavy drinkers develop alcoholic hepatitis; genetic susceptibility, nutritional status, gender (women are more susceptible at lower consumption levels), and pattern of drinking all influence risk. The condition represents one of the most severe presentations within the spectrum of alcohol-associated liver disease.

What corticosteroid regimen is used for severe alcoholic hepatitis?

The standard corticosteroid regimen for severe alcoholic hepatitis is prednisolone 40 mg daily for 28 days. Prednisolone is preferred over prednisone because the latter requires hepatic conversion to its active form, which may be impaired in severe liver disease. Treatment response should be assessed at day 7 using the Lille score. If the Lille score is 0.45 or above (indicating non-response), discontinuation of corticosteroids should be considered to avoid unnecessary immunosuppression. If the patient is responding (Lille below 0.45), the 28-day course should be completed.

What are the contraindications to corticosteroids in alcoholic hepatitis?

Contraindications to corticosteroid therapy in alcoholic hepatitis include active or uncontrolled infection or sepsis, active gastrointestinal bleeding, hepatorenal syndrome (particularly type 1), acute pancreatitis, poorly controlled diabetes mellitus, and active tuberculosis. Patients with these conditions require alternative management strategies, as corticosteroids may worsen these concurrent conditions. In some centers, pentoxifylline has been used as an alternative, though evidence for its efficacy is less robust than for corticosteroids.

How does the Lille score complement the GAHS?

The GAHS and Lille score serve complementary roles in managing alcoholic hepatitis. The GAHS is used at admission (and days 6 through 9) to assess prognosis and guide the decision to initiate corticosteroid therapy. The Lille score is calculated at day 7 of corticosteroid treatment to assess treatment response. Together, they form a sequential decision-making framework: the GAHS identifies who should receive corticosteroids, and the Lille score determines who should continue them. This two-stage approach optimizes treatment by maximizing benefit while minimizing unnecessary corticosteroid exposure.

What is the Modified Maddrey Discriminant Function?

The modified Maddrey Discriminant Function (mDF) is calculated as 4.6 multiplied by the difference between the patient’s prothrombin time and the control prothrombin time (in seconds), plus the serum bilirubin in mg/dL (or umol/L divided by 17.1). An mDF of 32 or greater indicates severe alcoholic hepatitis. While widely used and highly sensitive, the mDF has notable limitations including poor specificity (high false-positive rate for predicting death) and reliance on only two parameters. The GAHS was developed partly to address these limitations.

Can the GAHS be used in patients who are already on corticosteroids?

The GAHS was primarily validated in treatment-naive patients and in the context of deciding whether to initiate corticosteroids. While the score can be calculated in patients already receiving treatment, interpretation should be done with caution, as corticosteroids may influence some of the component parameters (particularly WBC, which may rise with steroid use). For assessing treatment response in patients already on corticosteroids, the Lille score at day 7 is the recommended tool rather than serial GAHS calculations.

What guidelines endorse the use of GAHS?

The GAHS is endorsed by the 2018 European Association for the Study of the Liver (EASL) Clinical Practice Guidelines on the Management of Alcohol-Related Liver Disease, which recommends it alongside the mDF and Lille score as part of the prognostic assessment toolkit. The American College of Gastroenterology (ACG) and the American Association for the Study of Liver Diseases (AASLD) also reference prognostic scoring in alcoholic hepatitis, though specific guideline recommendations vary between organizations regarding which score is preferred.

What is the prognosis for patients with a GAHS of 9 or above who receive corticosteroids?

In validation studies, patients with a GAHS of 9 or above who received corticosteroid treatment had a 28-day survival of approximately 78%, compared with only 52% in untreated patients with the same score threshold. The 84-day survival also showed improvement with treatment. This represents a clinically meaningful survival benefit and underscores the importance of identifying these high-risk patients for timely treatment. However, not all patients respond to corticosteroids, and the Lille score at day 7 should be used to confirm treatment response.

How is alcoholic hepatitis diagnosed?

Alcoholic hepatitis is typically diagnosed clinically based on a combination of history, examination findings, and laboratory results. Key features include a history of heavy alcohol consumption (usually 50 grams or more daily for at least 6 months, with drinking within the past 8 weeks), jaundice (serum bilirubin above 51 umol/L or 3 mg/dL), elevated AST (typically below 300 IU/L with AST/ALT ratio greater than 1.5), and exclusion of other causes of liver disease. Liver biopsy is the gold standard for diagnosis but is not always required if the clinical presentation is characteristic.

What happens if a patient’s GAHS changes between day 1 and day 6 through 9?

Changes in the GAHS between the initial assessment and reassessment provide dynamic prognostic information. A patient whose score decreases below 9 by days 6 through 9 has an improved prognosis compared to the initial assessment, suggesting a favorable response to supportive care. Conversely, a patient whose score increases or remains at 9 or above has a persistently poor outlook and may need intensified management. This dynamic assessment is one of the strengths of the GAHS, allowing clinicians to update their prognostic estimates as the clinical picture evolves.

Are there any newer alternatives to the GAHS for alcoholic hepatitis prognosis?

Research continues to explore improved prognostic tools for alcoholic hepatitis. Emerging biomarkers including cytokeratin-18 (a marker of hepatocyte apoptosis), C-reactive protein, and various cytokine levels have shown promise in predicting outcomes. The MELD-Na score, which adds sodium to the traditional MELD calculation, has also been evaluated. Composite approaches that combine multiple existing scores or incorporate novel biomarkers may offer improved accuracy. However, the GAHS remains a well-validated, practical tool that requires only routine laboratory tests, making it widely applicable in clinical settings worldwide.

What is the recommended alcohol intake threshold for diagnosing alcoholic hepatitis?

The commonly cited threshold for alcohol consumption associated with alcoholic hepatitis is 50 grams or more per day, which is approximately equivalent to 4 or more standard drinks daily. However, this threshold varies between guidelines and populations. Some guidelines use lower thresholds, such as 40 grams per day for women and 60 grams for men. It is important to note that not all individuals consuming above these thresholds develop alcoholic hepatitis, and genetic factors, nutritional status, and drinking pattern all modify individual susceptibility. A standard drink contains approximately 14 grams of alcohol in the United States and 8 to 10 grams in many European and Asian countries.

Can the GAHS calculator be used by non-physicians?

While this calculator can technically be used by anyone to compute a GAHS value, interpretation and clinical decision-making based on the score should only be performed by qualified healthcare professionals, including physicians, hepatologists, gastroenterologists, and other specialists experienced in managing liver disease. The score is one component of a complex clinical assessment and should never be used in isolation to make treatment decisions. Patients should not attempt to self-diagnose or self-treat based on calculator results.

What follow-up is needed after calculating the GAHS?

After calculating the GAHS, several follow-up steps are important. For patients with GAHS below 9: continue supportive care, monitor closely, and reassess the GAHS on days 6 through 9. For patients with GAHS of 9 or above: screen for contraindications to corticosteroids, consider initiating prednisolone 40 mg daily, calculate the Lille score at day 7 of treatment, and if the Lille score indicates non-response, consider discontinuing corticosteroids. All patients should be counseled on absolute alcohol abstinence, assessed for nutritional status, and considered for referral to addiction medicine or alcohol cessation programs.

Conclusion

The Glasgow Alcoholic Hepatitis Score represents a significant advancement in the prognostic assessment of alcoholic hepatitis, offering superior accuracy compared to the widely used modified Maddrey Discriminant Function. By incorporating five readily available parameters that capture hepatic synthetic function, renal function, systemic inflammation, and patient age, the GAHS provides a comprehensive snapshot of disease severity that directly informs treatment decisions.

The critical threshold of 9 serves as a practical decision point: patients scoring 9 or above face substantially increased mortality risk and represent the population most likely to benefit from corticosteroid therapy. Patients below this threshold can generally be managed with supportive care, potentially sparing them from unnecessary corticosteroid exposure. The ability to reassess the score on days 6 through 9 adds valuable dynamic prognostic information.

As endorsed by international guidelines including EASL 2018, the GAHS should be considered a standard component of the prognostic toolkit for alcoholic hepatitis alongside the mDF and Lille score. Healthcare providers worldwide are encouraged to incorporate this validated scoring system into their clinical practice to optimize patient outcomes in this challenging and increasingly prevalent condition.